Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
STRATA Skin Sciences (NASDAQ: SSKN) announced it will release its fourth quarter and full year 2021 financial results on March 21, 2022, followed by a conference call at 4:30 p.m. ET. The call will review financial performance and provide corporate updates. STRATA focuses on developing innovative dermatological products, including excimer lasers and treatment systems for conditions like psoriasis and acne, targeting a significant patient base in the U.S.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company focused on dermatologic treatment, will participate in the Oppenheimer 32nd Annual Healthcare Conference. Management is set to present on March 15 at 2:00 pm ET and will engage in one-on-one meetings throughout the day. A live and archived webcast of the presentation will be accessible on the company's investor website. STRATA offers advanced products like the XTRAC excimer lasers and TheraClear system, addressing conditions such as psoriasis and acne, impacting over 31 million patients in the U.S.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has appointed Dr. Patricia S. Walker to its Board of Directors, effective February 14, 2022. With over 35 years of experience in dermatology and corporate leadership in medical aesthetics and pharmaceuticals, Dr. Walker's expertise in clinical research and strategic initiatives is expected to enhance STRATA’s operations. Previously, she was the Chief Scientific Officer at Brickell Biotech and has served in key roles at Allergan and Kythera Biopharmaceuticals. Dr. Walker aims to contribute significantly to STRATA’s growth in treating dermatologic conditions and improving patient outcomes.
STRATA Skin Sciences (NASDAQ: SSKN) has launched its next-generation excimer laser system, XTRAC Momentum™ 1.0, in the U.S. The device targets UVB light therapy for skin conditions like psoriasis, atopic dermatitis, and vitiligo. The new system boasts higher power and faster repetition rates, enhancing patient experience. The global treatment market for these conditions surpasses $33 billion, with projected growth. STRATA aims to expand its market footprint with innovative, non-systemic solutions, affirming its commitment to dermatology.
STRATA Skin Sciences has signed an agreement with JuvenIL, a leading distributor in Israel, to market its XTRAC excimer lasers targeting around 300,000 psoriasis and 160,000 vitiligo patients in the country. STRATA’s President & CEO, Robert Moccia, expressed confidence in this partnership as a strategic opportunity to expand into the Israeli market. JuvenIL will leverage its extensive network among over 40 hospitals and 4 Health Maintenance Organizations to commercialize the products effectively.
STRATA Skin Sciences (NASDAQ: SSKN) reported preliminary fourth quarter 2021 revenue between $8.8 million and $9.2 million, up from $6.7 million in Q4 2020. Full-year revenue for 2021 is expected between $29.7 million and $30.1 million, compared to $23.1 million in 2020. Cash and equivalents totaled $12.5 million on December 31, 2021, down from $18.1 million the previous year. The company placed 34 XTRAC systems and expanded its international clinics significantly. STRATA also acquired assets from Theravant Corporation, enabling entry into the $5.5 billion U.S. acne care market.
STRATA Skin Sciences (NASDAQ: SSKN) has announced the acquisition of Theravant Corporation's TheraClear System, enhancing its position in the $5.5 billion acne care market. The deal involves an upfront payment of $1 million, comprising $500,000 in cash and $500,000 in common stock, with additional milestone-based payments. This acquisition allows STRATA to leverage its marketing platform to expand its product offerings beyond acne treatments. TheraClear's FDA-cleared system promises effective in-office treatment for various acne types, aiming to enhance patient compliance and satisfaction.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced participation in the H.C. Wainwright Bioconnect Virtual Conference, with a pre-recorded presentation set for January 10, 2022, at 7:00 am ET. The presentation will be accessible via the investor section of their website. STRATA focuses on innovative dermatology treatments, offering products like XTRAC and Pharos excimer lasers, which treat skin conditions affecting over 31 million patients in the U.S. Their strategy includes direct-to-consumer advertising to boost awareness and support partner clinics through in-house services.
STRATA Skin Sciences (NASDAQ: SSKN) announced the appointment of Douglas Strang to its Board of Directors, effective October 27, 2021. Strang, a former partner at PwC, will serve as Audit Committee Chair following LuAnn Via's departure on December 31, 2021. With a 35-year career in life sciences and extensive experience in financial audits and risk management, Strang aims to enhance STRATA's growth in the dermatology sector. The company, known for its XTRAC laser system, anticipates strong momentum in 2022 and beyond.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) reported Q3 2021 revenues of $7.7 million, a 37.4% increase year-over-year. Recurring revenues rose 48.9% to $5.7 million. The company achieved gross margins of 69.7%, up 12.2% from Q3 2020. STRATA entered an $8 million credit agreement, enhancing its financial flexibility. Cash and equivalents stood at $13.1 million at the end of Q3. The company anticipates returning to pre-COVID revenue levels by year-end 2021, bolstered by its acquisition of Ra Medical Systems' dermatology business.
FAQ
What is the current stock price of Strata Skin Sciences (SSKN)?
What is the market cap of Strata Skin Sciences (SSKN)?
